Immunology
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global immunology drug development, market trends, and regulatory landscapes. Inform your pharma BD and investment strategy.
Showing 1–6 of 6 articles
Quick answer
NovaPharmaNews Immunology hub for NMPA covers 6 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases
Kodiak Sciences KSI-101 Clinical Data to Be Presented at Scientific Conferences for Macular Edema Treatment
Vivacta Bio Raises $50M+ Series A Funding for GT801 CAR-T Gene Therapy Development
Samsung Bioepis Begins Phase 1 Trial for Novel ADC SBE303, Expands Sandoz Biosimilar Partnership
Biogen Acquires Felzartamab Rights from TJ Biopharma for Greater China Market
Zai Lab's ZL-1503 Bispecific Antibody Shows Promise for Rapid Itch Relief in Atopic Diseases
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.